Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians

Journal of General Internal Medicine

Volumn 22, Issue 9, 2007, Pages 1325-1329

  Cunningham, Chinazo O ^a   Kunins, Hillary V ^a   Roose, Robert J ^a   Elam, Rashiah T ^a   Sohler, Nancy L ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b CITY UNIVERSITY OF NEW YORK MEDICAL SCHOOL   (United States)

Author keywords

Barriers; Buprenorphine; HIV; Substance abuse

Indexed keywords

BUPRENORPHINE; OPIATE;

ADULT; ARTICLE; BIVARIATE ANALYSIS; CHI SQUARE TEST; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG ABUSE; FEMALE; HEALTH SURVEY; HIV EDUCATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LOGISTIC REGRESSION ANALYSIS; MALE; MEDICAL EDUCATION; MEDICAL SPECIALIST; NORMAL HUMAN; OPIATE ADDICTION; PHYSICIAN; PHYSICIAN ATTITUDE; PRESCRIPTION; QUESTIONNAIRE; RISK FACTOR; SEX DIFFERENCE; STUDENT T TEST;

ADULT; BUPRENORPHINE; CROSS-SECTIONAL STUDIES; DRUG AND NARCOTIC CONTROL; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; OPIOID-RELATED DISORDERS; PRESCRIPTIONS, DRUG;

EID: 34547850468     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-007-0264-7     Document Type: Article

References (34)

1. Centers for Disease Control and Prevention. HIV/AIDS surveillance report, 2005, vol. 17. 2006. Atlanta Ga: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2006, 1-47. Accessed 20 Jan 2007 at http://www.cdc.gov/hiv/topics/surveillance/resources/reports/.
2. Fleishman JA, Gebo KA, Reilly ED, et al. Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002. Med Care. 2005;43(9 suppl):40-52.
3. Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA. 1999;281(24):2305-15.
4. Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17(5):377-81.
5. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131(2):81-7.
6. Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27(3):251-9.
7. Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002;16(5):767-74.
8. Palepu A, Horton NJ, Tibbetts N, Meli S, Samet JH. Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: the impact of substance abuse treatment. Addiction. 2004;99(3):361-8.
9. Department of Health and Mental Hygiene. New York City HIV/AIDS annual surveillance statistics. New York: New York City Department of Health and Mental Hygiene; 2006. Accessed 25 Jan 2007 at http://www.nyc.gov/html/doh/html/ah/ hivtables.shtml (Updated 4 Dec 2006).
10. Samet JH, Friedmann P, Saitz R. Benefits of linking primary medical care and substance abuse services: patient, provider, and societal perspectives. Arch Intern Med. 2001;161(1):85-91.
11. Selwyn PA, Budner NS, Wasserman WC, Arno PS. Utilization of on-site primary care services by HIV-seropositive and seronegative drug users in a methadone maintenance program. Public Health Rep. 1993;108(4):492-500.
12. Department of Health and Human Services Substance Abuse and Mental Health Services Administration. Results from the 2005 National Survey on Drug Use and Health: detailed tables. Rockville, Md: Department of Health and Human Services Substance Abuse and Mental Health Services Administration, Office of Applied Sciences; 2006. Accessed 20 Jan 2007 at http://oas.samhsa.gov/NSDUH/2k5nsduh/ tabs/2k5TabsCover.pdf.
13. Office of National Drug Control Policy. Consultation document on opioid agonist treatment; 2003. Accessed 20 Jan 2007 at http://www. whitehousedrugpolicy.gov/science%5Ftech/methadone/metha3.html.
14. Kissin W, McLeod C, Sonnefeld J, Stanton A. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. J Addict Dis. 2006;25(4):91-103.
15. Saitz R, Friedmann PD, Sullivan LM, et al. Professional satisfaction experienced when caring for substance-abusing patients: faculty and resident physician perspectives. J Gen Intern Med. 2002;17(5):373-6.
16. Turner BJ, Laine C, Lin YT, Lynch K. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence. Arch Intern Med 2005;165(15):1769-76.
17. Johnson TP, Booth AL, Johnson P. Physician beliefs about substance misuse and its treatment: findings from a U.S. survey of primary care practitioners. Subst Use Misuse. 2005;40(8):1071-84.
18. Friedmann PD, McCullough D, Saitz R. Screening and intervention for illicit drug abuse: a national survey of primary care physicians and psychiatrists. Arch Intern Med. 2001;161(2):248-51.
19. Geller G, Levine DM, Mamon JA, Moore RD, Bone LR, Stokes EJ. Knowledge, attitudes, and reported practices of medical students and house staff regarding the diagnosis and treatment of alcoholism. JAMA. 1989;261(21):3115-20.
20. Cunningham CO, Sohler NL, McCoy K, Kunins HV. Attending physicians' and residents' attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital. Fam Med. 2006;38(5):336-40.
21. Sullivan LE, Tetrault J, Bangalore D, Fiellin DA. Training HIV physicians to prescribe buprenorphine for opioid dependence. Subst Abuse. 2006;27(3):13-18.
22. Becker WC, Fiellin DA. Provider satisfaction with office-based treatment of opioid dependence. A systematic review. Subst Abuse. 2006;26(1):15-22.
23. West JC, Kosten TR, Wilk J, et al. Challenges in increasing access to buprenorphine treatment for opiate addiction. Am J Addict. 2004;13(suppl 1):S8-16.
24. Chappel JN, Veach TL, Krug RS. The substance abuse attitude survey: an instrument for measuring attitudes. J Stud Alcohol. 1985;46(1):48-52.
25. Hosmer DW, Lemeshow S. Applied logistic regression, 2nd ed. Hoboken, NJ: John Wiley & Sons, Inc.; 2000.
26. Friedmann PD, McCullough D, Chin MH, Saitz R. Screening and intervention for alcohol problems. A national survey of primary care physicians and psychiatrists. J Gen Intern Med. 2000;15(2):84-91.
27. Gottlieb NH, Mullen PD, McAlister AL. Patients' substance abuse and the primary care physician: patterns of practice. Addict Behav. 1987;12(1):23-32.
28. Ford C, Ryrie IA. A comprehensive package of support to facilitate the treatment of problem drug users in primary care: an evaluation of the training component. Int J Drug Policy. 2000;11(6):387-92.
29. Miller NS, Sheppard LM, Colenda CC, Magen J. Why physicians are unprepared to treat patients who have alcohol- and drug-related disorders. Acad Med. 2001;76(5):410-18.
30. Park ER, Wolfe TJ, Gokhale M, Winickoff JP, Rigotti NA. Perceived preparedness to provide preventive counseling: reports of graduating primary care residents at academic health centers. J Gen Intern Med. 2005;20(5):386-91.
31. Isaacson JH, Fleming M, Kraus M, Kahn R, Mundt M. A national survey of training in substance use disorders in residency programs. J Stud Alcohol. 2000;61(6):912-15.
32. Fleming MF, Manwell LB, Kraus M, Isaacson JH, Kahn R, Stauffacher EA. Who teaches residents about the prevention and treatment of substance use disorders? A national survey. J Fam Pract. 1999;48(9):725-29.
33. Fleming M, Barry K, Davis A, Kropp S, Kahn R, Rivo M. Medical education about substance abuse: changes in curriculum and faculty between 1976 and 1992. Acad Med. 1994;69(5):362-9.
34. SAMHSA/CSAT. SAMHSA/CSAT Evaluation of the Buprenorphine Waiver Program. Presented at the American Society of Addiction Medicine, May 2006. Accessed 24 May 2007 at http://buprenorphine.samhsa.gov/ASAM_06_Final_Results.pdf.